← Human Trials & Peer-Reviewed Studies
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
Plain-language guide to PMID 37355043 (2023): open-label randomized controlled trial study of Semaglutide and Efinopegdutide, fatty liver & elevated liver enzymes.
Key Facts
- PMID
- 37355043
- Journal
- Journal of hepatology
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Romero-Gómez M et al. (8 authors)
- DOI
- 10.1016/j.jhep.2023.05.013
- Registered trial
- NCT04944992
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Semaglutide and Efinopegdutide in the context of fatty liver & elevated liver enzymes, published as a randomized controlled trial.
This study assessed the effects of the glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist efinopegdutide relative to the selective GLP-1 receptor agonist semaglutide on liver fat content (LFC) in patients with non-alcoholic fatty liver disease (NAFLD).
A magnetic resonance imaging-estimated proton density fat fraction assessment was performed to determine LFC at screening and Week 24.
Who Took Part
Participants were stratified according to the concurrent diagnosis of type 2 diabetes mellitus (T2DM).
How the Study Was Run
The design is described as randomized, open-label and parallel-group.
The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.
Being open-label, the Semaglutide study did not mask who received what.
The Semaglutide group and the comparison group ran side by side rather than switching.
This was a phase IIa, randomized, active-comparator-controlled, parallel-group, open-label study.
What Was Measured
PubMed files the paper under topics including Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor, Hypoglycemic Agents, Non-alcoholic Fatty Liver Disease, Weight Loss and Glucagon-Like Peptide-1 Receptor Agonists.
Author keywords: efinopegdutide, liver fat content, nonalcoholic fatty liver disease and semaglutide.
What This Means in Plain Language
The paper is a randomized, open-label and parallel-group study of Semaglutide and Efinopegdutide in people with fatty liver & elevated liver enzymes.
The abstract goes on to report its results in about 10 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2023 (Journal of hepatology), a journal based in Netherlands.
More context: the Semaglutide compound page and the Efinopegdutide compound page, Fatty liver & elevated liver enzymes research.
Our Notes on the Compounds
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Efinopegdutide: A long-acting GLP-1/glucagon dual agonist from Merck studied for MASH.
Related Pages
- Fatty liver & elevated liver enzymes research
- Semaglutide in the library
- Efinopegdutide in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.